4//SEC Filing
Rochlin Kate 4
Accession 0001415889-24-024871
CIK 0001740279other
Filed
Oct 7, 8:00 PM ET
Accepted
Oct 8, 4:15 PM ET
Size
12.4 KB
Accession
0001415889-24-024871
Insider Transaction Report
Form 4
IN8BIO, INC.INAB
Rochlin Kate
Chief Operating Officer
Transactions
- Award
Common Stock
2024-10-04+25,316→ 42,874 total - Disposition to Issuer
Series A Warrants (right to buy)
2024-10-04−12,295→ 0 totalExercise: $1.25Exp: 2025-06-13→ Common Stock (12,295 underlying) - Award
Series A Warrants (right to buy)
2024-10-04+12,295→ 12,295 totalExercise: $0.45Exp: 2025-10-04→ Common Stock (12,295 underlying) - Award
Series C Warrants (right to buy)
2024-10-04+25,316→ 25,316 totalExercise: $0.27Exp: 2027-10-04→ Common Stock (25,316 underlying)
Footnotes (4)
- [F1]The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock.
- [F2]The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025.
- [F3]Fully vested and exercisable.
- [F4]The reported securities are included within 12,295 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock.
Documents
Issuer
IN8BIO, INC.
CIK 0001740279
Entity typeother
Related Parties
1- filerCIK 0001898521
Filing Metadata
- Form type
- 4
- Filed
- Oct 7, 8:00 PM ET
- Accepted
- Oct 8, 4:15 PM ET
- Size
- 12.4 KB